FDA Clearance Tracker · P160049
STELLAREX 0.035 OTW DRUG-COATED ANGIOPLASTY BALLOON
Last checked: Nov 20, 2026Latest source record: Jul 26, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Jul 26, 2017
Approved
Time to decision
266 days
Received Nov 2, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P160049
- Device name
- STELLAREX 0.035 OTW DRUG-COATED ANGIOPLASTY BALLOON
- Applicant
- The Spectranetics Corp.
- Applicant location
- Fremont, CA
- Received
- Nov 2, 2016
- Decided
- Jul 26, 2017
- Decision
- Approved
- Supplements
- 24 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval of the Stellarex 0.035 OTW Drug-coated Angioplasty Balloon. This device is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code ONU. The earliest in FDA's data is P130024, decided Oct 9, 2014.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for The Spectranetics Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Stellarex 0.035OTW Drug-coated Angioplasty BalloonPMA supplement
P160049-S015 · Decided Mar 25, 2022 · 177 days after receipt · Panel Track
Device type: Drug-Eluting Peripheral Transluminal Angioplasty Catheter (ONU) · Cardiology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.